Determination of the carrier-type at III-nitride semiconductor surfaces/interfaces using contactless electroreflectance

1998 ◽  
Vol 72 (11) ◽  
pp. 1353-1355 ◽  
Author(s):  
Wojciech Krystek ◽  
Fred H. Pollak ◽  
Z. C. Feng ◽  
M. Schurman ◽  
R. A. Stall
Keyword(s):  
Semiconductor Surfaces ◽  
Nitride Semiconductor ◽  
At Iii

Changes In Biologically And Immunochemically Measured Antithrombin III (At III) In Total HIP Replacement With Special Regard To Type Of Thromboembolic Prophylaxis

1981 ◽  
Author(s):  
H O Fredin ◽  
L Tengborn
Keyword(s):  
Total Hip Replacement ◽  
Hip Replacement ◽  
Antithrombin Iii ◽  
Screening Method ◽  
Chromogenic Substrate ◽  
Thromboembolic Prophylaxis ◽  
Total Hip ◽  
At Iii ◽  
Lung Scanning

The plasma levels of AT III were studied in 71 patients operated with total hip replacement. AT III was determined with amidolytic assay using the chromogenic substrate Coatest S-2238 (KabiDiagnostica, Sweden) as well as electroimmunochemically. Samples were drawn before the operation and 4-5 times the first week postoperatively. The results were adjusted to the hematocrit (Hcr) for each sample.The patients were randomly allocated to thromboprophylactic prevention with either Macrodex (Pharmacia, Sweden) or heparin with dihydroergotamine (Sandoz, Switzerland). Phlebography of the operated leg and perfusion/ventilation lung scanning was performed on the 10-14th postoperative day.Results. No difference in the AT III levels were seen in patients who developed postoperatively deep venous thrombosis and/or pulmonary embolism (DVT/PE) as compared to those who did not develop DVT/PE.No decrease of AT III was found postoperatively, when adjusted to HcrThe frequency of DVT/PE did not differ significantly between the two types of thromboembolic prophylaxis.Conclusion. Pre-operative determination of AT III, whether biologically or immunochemically, did not seem to be successful as screening method of patients to develop DVT/PE.

Chemical reactions of ammonia with polar and non-polar nitride semiconductor surfaces

1999 ◽  
Vol 427-428 ◽  
pp. 298-303 ◽  
Author(s):  
J. Fritsch ◽  
O.F. Sankey ◽  
K.E. Schmidt ◽  
J.B. Page
Keyword(s):  
Chemical Reactions ◽  
Semiconductor Surfaces ◽  
Nitride Semiconductor

Determination of stability constants between complexing agents and At(I) and At(III) species present at ultra-trace concentrations

2009 ◽  
Vol 362 (8) ◽  
pp. 2654-2661 ◽  
Author(s):  
J. Champion ◽  
C. Alliot ◽  
S. Huclier ◽  
D. Deniaud ◽  
Z. Asfari ◽  
...  
Keyword(s):  
Stability Constants ◽  
Complexing Agents ◽  
At Iii ◽  
Ultra Trace ◽  
Trace Concentrations

Assay of Heparin in Plasma Using a Chromogenic Substrate and It’s Clinical Applications

1979 ◽  
Author(s):  
Y. Oguma ◽  
T. Seya ◽  
T. Murakoshi ◽  
M. Yamauchi ◽  
H. Nagata ◽  
...  
Keyword(s):  
Clinical Benefit ◽  
Normal Values ◽  
Regression Line ◽  
Subcutaneous Administration ◽  
Clinical Applications ◽  
Chromogenic Substrate ◽  
At Iii ◽  
Thrombotic Diseases ◽  
And Control

Heparin (HR) has been used for cht treatment of thrombotic diseases. Many problems, however, still remain to be resolved in HR therapy. This paper deals with : 1) Clinical benefit of the assay of plasma HR by the chromogenic substrate (Kabi Diagnostica). 2) Correlation between plasma HR and APTT.3) Clinical usefulnesa of subcutaneous administration of HR.4) Correlation between the concentration of plasma AT III and the et-feet of HR. The determination of plasma HR by this procedure can bperformed easily, promptly and acculately in the range of 0.1-0.8 IU/ml of therapeutic HR concentration. Therefore, It Is quite effective for the evaluation and control of practical HR therapy. A significant correlation between the. HR concentration and APTT was observed in each case. However, each regression line was quite different. In many cases, the therapeutic HR concentration was continued by every 12 hre subcutaneous administration or HK calcium (250 IU/kg). But this procedure was not effective in a case of shock with DIC. If the patient’s plasma contains at least 501 of the AT III of normal values, there are no problems in HR therapy.

scholarly journals Differential Determination of Antithrombin Activities of Plasma Antithrombin III and α2-Macroglobulin

1977 ◽  
Author(s):  
T. Matsuda ◽  
M. Ogawara ◽  
N. Hirabayashi ◽  
T. Seki ◽  
M. Murakami
Keyword(s):  
Healthy Subjects ◽  
Antithrombin Iii ◽  
Radial Immunodiffusion ◽  
Thrombin Inhibitors ◽  
Healthy Individuals ◽  
Single Radial Immunodiffusion ◽  
Antithrombin Activity ◽  
Α2 Macroglobulin ◽  
At Iii

Among several thrombin inhibitors in normal plasma, antithrombin III (AT-III) and α2-macroglobulin (α2-M) are especially important.However, there has been no appropriate method to determine AT-III and α2-M separately. This study was carried out to differentiate the actions of these two inhibitors of thrombin in plasma. By using single radial immunodiffusion method, we observed that AT-III was adsorbed to bentonite, although α2-M was not. It was necessary to incubate 1 ml of oxalated plasma with 300 mg of bentonite at 37°C for 10 minutes to remove AT-III completely. Supernated plasma contains neither AT-III nor fibrinogen which affects antithrombin activity of plasma. From these results, it is evident that antithrombin activity of plasma adsorbed with bentonite was attributed to that of α2-M. Antithrombin activities of plasma adsorbed with bentonite in 20 healthy subjects were significantly correlated with concentrations of α2-M in plasma, measured immunologically (r=+0.87, p<0.001). It is reasonable to presume that difference between antithrombin activity of defibrinated plasma by heating at 56°C for 2 minutes and that of bentonite treated plasma mainly indicates activity of AT-III. These differences measured in 20 healthy individuals were significantly correlated with plasma AT-TH levels, assayed immunochemically (r=+0.53, p<0.01).

A Method for the Quantitative Determination of the Antithrombin III (AT III) a Citivity in Plasma and Serum Using the Complex Formation with Heparin

1975 ◽  
Author(s):  
H. E. Karges ◽  
N. Heimburger ◽  
C. Loechelt
Keyword(s):  
Plasma Concentration ◽  
Antithrombin Iii ◽  
Ph Value ◽  
Immunological Methods ◽  
Good Reproducibility ◽  
High Dilution ◽  
At Iii ◽  
The Mean ◽  
Native Plasma

A prerequisite of most AT III assays is the defibrination of the samples. Defibrination of plasma, however, is generally associated with a loss of AT III. This especially true of heat defibrination. Furthermore, according to our experience, most of the functional determinations don’t correlate well with the immunological ones, and don’t provide reproducible results. Therefore, it was the aim of our investigations to establish a method which omits the defibrination and yields reproducible results.The method reported is based on the identity of AT III and heparin cofactor antithrombin II (AT II) respectively. AT III is converted by heparin from a progressive into an immediate inhibitor, allowing a plasma dilution of 1:50. Due to this high dilution, the defibrination step can be omitted and AT III determined in native plasma. To transform AT III completely into its heparin complex, 5 USP units heparin are used. α2-macro-globulin up to 400% of normal plasma concentration does not influence the assay. When determinations are performed at a certain pH value, good reproducibility is obtained. The mean error of determinations of the same sample does not exeed 4%. Maximal deviations were in the range of 5 to 10%. The results of functional determinations are compared with those obtained by two immunological methods. Deviations scarcely exeed the limits of methodical errors.

Sign in / Sign up

Export Citation Format

Share Document